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Methylphenidate (MPH) abuse causes adverse neurobehavioral and neurochemical effects. Some herbal components such as 
crocin have shown neuroprotective properties. The current study evaluates the potential role of the cyclic AMP response element 
binding protein (CREB)‑brain‑derived neurotrophic factor (BDNF) signaling pathway in mediating the neuroprotective effects of 
crocin against MPH‑induced neurotoxicity in rats. Seventy adult male rats were randomly divided into seven groups. Group 1 
and 2 received 0.7 ml/rat of normal saline and 10 mg/kg of MPH, respectively. Groups 3, 4, 5, and 6 were treated simultaneously 
with MPH (10 mg/kg) and crocin (10, 20, 40, and 80 mg/kg, respectively) for 21 days. Group 7 was treated with crocin (80 mg/kg) 
alone for 21  days. The Morris water maze (MWM) and open field test were used to assess cognitive and locomotor activities. 
Hippocampal neurotoxicity parameters and levels of BDNF and CREB were evaluated. Simultaneous treatment with various doses 
of crocin reduced the MPH‑induced cognition disturbances and hyperlocomotion. In addition, lipid peroxidation increased with 
MPH treatment and levels of the oxidized forms of glutathione (GSSG), interleukin 1 beta (IL‑1β), tumor necrosis factor alpha 
(TNF‑α), and Bax increased. MPH treatment decreased levels of the reduced form of glutathione (GSH), P‑CREB, Bcl‑2, and BDNF in 
the hippocampus. MPH also reduced activity of superoxide dismutase, glutathione peroxidase, and glutathione reductase in the 
hippocampus. In contrast, crocin attenuated MPH‑induced oxidative stress, inflammation, and apoptosis, and increased levels of 
P‑CREB and BDNF. Thus, crocin – likely via stimulation of the P‑CREB/BDNF signaling pathway – displayed neuroprotection against 
MPH‑induced neurotoxicity.
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INTRODUCTION 
Abuse of methylphenidate (MPH), a neurostimu‑
lating agent, has increased in recent years (Martins 
et al., 2006). MPH has been used for the management 
of attention/deficit hyperactivity disorder (ADHD) in 
children, and is the drug of choice in the treatment 
of ADHD (Leonard et al., 2004). The consequences of 
chronic use of MPH and its biochemical and behavior‑
al effects remain unclear (Morton and Stockton, 2000; 
Martins et al., 2006). MPH increases the release of dopa‑
mine, norepinephrine, and to a lesser extent, serotonin 
into synaptic terminals (Morton and Stockton, 2000). 
MPH also causes hyperstimulation of receptors in the 
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acute phases, and downregulation of its receptor in the 
chronic phase (Peles et al., 2015). The pharmacological 
actions of MPH are similar to cocaine, and this simi‑
larity causes a high potential for abuse and addiction 
(Vendruscolo et al., 2008; Peles et al., 2015). Prolonged 
abuse of MPH can prompt behavioral changes such as 
anxiety and depression‑like behavior, and also result 
in cognitive (e.g., learning and memory) impairments 
in rodent experimental models (Leonard et al., 2004). 
Previous studies have demonstrated that low doses and 
acute treatment of MPH can activate the glutamate re‑
ceptor, whereas high doses and chronic treatment of 
MPH can inhibit the glutamate receptor and this inhi‑
bition is responsible for the adverse cognitive effects 
(Cheng et al., 2014a; 2014b). MPH has different effects 
on the GABAergic system during chronic and acute 
treatment; indeed, previous studies have demonstrated 
that chronic MPH‑induced locomotion and repetitive 
movements were due to a decrease in GABA transmis‑
sion, whereas the GABAergic system was not signifi‑
cantly altered following acute MPH treatment (Freese 
et al., 2012; Goitia et al., 2013). Experimental studies 
have confirmed the potential effects of MPH on neuro‑
degeneration of several brain areas including the hip‑
pocampus, which is involved in cognition and anxiety 
(Andreazza et al., 2007; Jones and Dafny, 2013). In ad‑
dition, previous studies suggest that MPH has diverse 
effects on several brain areas such as the hippocampus, 
amygdalae, nucleus accumbens, and ventral tegmental 
area (Gray et al., 2007; Kim et al., 2009; Goitia et al., 
2013). Previous studies have demonstrated that MPH 
abuse can lead to the production of apoptotic proteins, 
such as Bax, caspase‑3, 8, and 9, which can result in 
DNA fragmentation in various brain regions including 
the hippocampus and amygdala (Martins et al., 2006; 
Andreazza et al., 2007). MPH and other neuro‑stimulant 
compounds can cause inflammation, oxidative stress, 
and mitochondrial dysfunction in brain cells; howev‑
er the putative mechanism underlying these effects 
remains unknown (Martins et al., 2006). Interestingly, 
MPH‑induced neurotoxicity seems to be more apparent 
in certain brain areas, particularly the hippocampus 
(including CA1, CA2, CA3, and DG subregions) and the 
amygdala (Morton and Stockton, 2000; Motaghinejad et 
al., 2017a).
In recent years, there has been a remarkable in‑
crease in the use of herbal/natural agents with ther‑
apeutic potential (Kanazawa et al., 2017). Natural fla‑
vonoids and their products are being extensively eval‑
uated as therapeutic compounds in the treatment of 
neurodegenerative disorders and some neuropsychiat‑
ric disorders induced by drug abuse (Kim, 2005; Kumar 
and Khanum, 2012). Crocin is a carotenoid chemical 
agent that is detected in the flowers Crocus sativus L 
and gardenia (Hosseinzadeh and Talebzadeh, 2005; Lee 
et al., 2005; Yousefsani et al., 2018). Crocin is the con‑
stituent that is the main cause of the color of saffron 
(Lee et al., 2005, Chen et al., 2008, Khalili et al., 2010). 
Crocin has been shown to act as an antioxidant (Chen 
et al., 2008; Mard et al., 2016) and a neuroprotective 
agent (Mehri et al., 2012). The antioxidant function of 
crocin is linked to the sugar moiety in the crocin mol‑
ecule, which plays a key role in its chemical reactivi‑
ty (Chen et al., 2008). In addition, crocin has potential 
antidepressant properties in mice and in humans (Hos‑
seinzadeh et al., 2009). The biological effects of crocin 
are mediated through antioxidant, anti‑inflammatory, 
antiapoptotic, and immunomodulatory activities (Hos‑
seinzadeh et al., 2005; 2009; Khalili and Hamzeh, 2010). 
Previous research demonstrates that treatment with 
crocin can counteract oxidative stress by lipid perox‑
idation reduction, and can improve the functioning 
of antioxidant enzymes such as superoxide dismutase 
(SOD) and catalase in some neurodegenerative dis‑
orders (Hosseinzadeh et al., 2005; El‑Beshbishy et al., 
2012). Also, one previous study indicated that chronic 
treatment of quercetin – an agent that is structurally 
similar to crocin – can inhibit the manic‑like and an‑
tioxidant effects of MPH treatment (Kanazawa et al., 
2017). Additionally, prolonged treatment with crocin 
decreased the alcohol‑induced increase in levels of in‑
terleukin 1 beta (IL‑1β) and tumor necrosis factor al‑
pha (TNF‑α) (El‑Maraghy et al., 2015). Taken together, 
all of these reported properties may contribute to the 
therapeutic potential efficacy of crocin in neurodegen‑
erative disorders related to drug abuse; however, the 
exact mechanism remains unclear (Tamaddonfard and 
Hamzeh‐Gooshchi, 2010: Firouzi et al., 2010; El‑Mara‑
ghy et al., 2015). Cyclic AMP response element binding 
protein (CREB) is a chief transcription factor that is 
responsible for the regulation of genes related to the 
synaptic activity and survival of neurons, neuroprotec‑
tion, and neural plasticity, such as the gene that en‑
codes brain‑derived neurotrophic factor (BDNF) (Carle‑
zon Jr et al., 2005; Motaghinejad et al., 2017b). BDNF 
is a significant neurotrophic factor that primarily sup‑
ports the development and survival of neurons. BDNF 
is highly expressed in certain brain regions that are 
implicated in the control of cognition, emotions, and 
rewards (Hattiangady et al., 2005; Lee et al., 2005). It 
has been proposed that crocin may protect hippocam‑
pal and frontal neurons from stress‑induced damage 
via an up‑regulation of CREB and BDNF; however, this 
hypothesis has not been confirmed. Therefore, the aim 
of this study was to evaluate the potential neuroprotec‑
tive role of crocin against MPH‑induced hippocampal 
impairment, and assess the potential mediating role of 
the P‑CREB‑BDNF signaling pathway in this process. 
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METHODS
Animals
Seventy adult Wistar male rats, weighing between 
250‑300 g, were purchased from the lab house of the 
Iran University of Medical Sciences. Rats were kept 
under controlled condition, i.e., in room temperature 
(22±0.5°C) with 12‑h light/dark cycles and free access 
to food and water.
Ethics statement
Our experimental procedure was approved by the 
Ethical Committee of the Iran University of Medical 
Sciences (IUMS) and is in accordance with the Guide‑
lines of Animal Ethics and Welfare. The guidelines of 
the IUMS were constructed in agreement with AR‑
RIVE (Animal Research: Reporting of In Vivo Experi‑
ments) procedures (Kilkenny et al., 2010). 
Drug
Crocin and MPH were obtained from Sigma‑Aldrich 




• Group 1 (i.e., the control group) was administered 
0.7 ml/rat, I.P., normal saline for 21 days.
• Group 2 (i.e., MPH) was given MPH (10 mg/kg, I.P.) 
for 21 days. 
• Groups 3, 4, 5 and 6 concurrently received MPH 
(10 mg/kg, I.P.) and crocin (with doses of 10, 20, 40, 
or 80 mg/kg, I.P.) for 21 days.
• Rats in Group 7 received crocin (80 mg/kg, I.P.) dis‑
solved in normal saline for 21 days. 
It should be noted that, in the groups treated with 
MPH in combination with crocin, administration of 
crocin was performed first. MPH was administered af‑
ter one hour. 
During the 17th and 21st days, the Morris water 
maze (MWM) task, a standard behavioral process for 
the evaluation of learning and spatial memory, was 
performed. In day 22, the open field test (OFT) was 
used as a standard test for the evaluation of locomo‑
tor changes in experimental animals. After the 22nd 
day, all animals were sacrificed and parameters for 
oxidative stress, inflammation, and apoptosis were 
measured in hippocampal tissues. Considering the im‑
portance of CREB signaling and its product, BDNF, the 
influence of crocin on MPH‑induced disorders in the 
CREB signaling pathway was studied in hippocampal 
tissues (Carlezon Jr et al., 2005; Motaghinejad et al., 
2016b; 2017d).
Behavioral method
Morris water maze task (MWM)
The MWM apparatus includes a circular tank 
(160 cm in diameter and 90 cm in height) that is black 
in color and filled with water. The apparatus was fixed 
in the center of the experimental lab. The apparatus 
was divided into four quadrants (north, east, west, and 
south), and water was filled to the height of 50 cm. The 
experimenter remained in the northeast corner of the 
room during testing. A disk on the platform with 15 cm 
diameter, which was hidden, was located 1 cm beneath 
the surface of the water. During the first four days of 
the experiment, the aforementioned platform was ran‑
domly inserted in the same quadrant of the tank. The 
position of the experimental animal in the tank was 
recorded by an automated infrared tracking system 
(CCTV B/W camera, SBC‑300 (P), Samsung Electronics 
Co, Ltd, Korea). The camera was placed 2.4 m above the 
surface of the water (D’Hooge and De Deyn, 2001; Vor‑
hees and Williams, 2006). 
Handling
On the first day, prior to the beginning of the ex‑
periment, all rats were positioned one‑by‑one in a tank 
that was filled with 40°C water, room temperature 
(25±2°C). The experimenter directed the rat to swim 
and to reach to the quadrant of the tank where the 
platform was placed. In our experiment, the platform 
was situated in the southeast quarter of the tank (Vor‑
hees and Williams, 2006; D’Hooge and De Deyn, 2001).
Training procedure
Some discriminating signs (for example, a distin‑
guished picture, window, door) were placed in the 
room to act as spatial cues for animals, to learn about 
the location of the platform. As mentioned above, the 
platform was positioned in the southeast quarter of 
the MWM tank, at a distance of 25 cm distance from 
the edge of the tank and 1 cm beneath the surface 
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of the water. For the evaluation of the learning pro‑
cedure, each rat was tested using four trials per day, 
for a total of four days. Each animal was randomly 
placed in one of the four quarters (north, east, west, 
and south). During the learning procedure, if the rats 
found the platform within 60 sec, the trial was auto‑
matically closed by a computer. However, if the ani‑
mals could not reach and found the platform within 
60 sec, the experiment was stopped automatically by 
the computer. In the learning experiment, two param‑
eters were evaluated: 
• The time of escape latency, characterized by the 
time to find the hidden platform.
• Distance traveled, which was quantified as the dis‑
tance each animal traveled to reach and find the 
hidden platform.
In the memory assessment procedure, on the fifth 
day (i.e., probe day), the platform was detached and 
animals were randomly placed of the water from one 
of the above‑mentioned directions (almost east), and 
the percentage of the presence of animal in the target 
quarter (i.e., the southeast quarter) was documented 
and calculated (D’Hooge and De Deyn, 2001; Vorhees 
and Williams, 2006).
Open field test (OFT)
The OFT, which is a standard test for assessment of 
locomotor activity in rodents, was performed accord‑
ing to previous studies (Gould et al., 2009). To assess 
locomotor activity in each animal, the following four 
behaviors were assessed: 
• Ambulation distance: the distance the rat crossed 
according to the grid lines.
• Center square entries: the number of times the rat 
crossed of one of the central red lines with all four 
paws, and entered into the central square. 
• Center square duration: the time the rat spent in 
the central square. 
• Rearing: the number of times the rat stood on their 
hind legs in the maze (Gould et al., 2009).
Mitochondrial preparations 
Animals were anesthetized using I.P. injections of 
sodium thiopental (50 mg/kg) and the hippocampus 
was isolated. After homogenization in cold buffer 
(25 mM 4‑morpho linepropanesulfonic acid, 400 mM 
sucrose, 4 mM magnesium chloride [MgCl2], 0.05 mM 
ethylene glycol tetraacetic acid [EGTA], pH 7.3), the 
homogenized tissues were centrifuged at 450 × g for 
10 min. The obtained supernatants were centrifuged 
again at 12000 × g for 10 min. At the end, the sediments 
were re‑suspended in homogenization buffer and 
stored at 0°C. Total mitochondrial proteins in tissues 
were measured using a Dc protein assay kit (Bio‑Rad), 
(California, USA). In brief, Bradford reagent (one part 
Bradford: four parts dH2O) was added to serial dilu‑
tion series (0.1‑1.0 mg/ml) of a known protein sample 
concentration; e.g., bovine serum albumin (BSA), dis‑
solved in homogenization buffer. These sequential di‑
lution series were prepared and used to create a stan‑
dard curve. Alternatively 10, 15, 20, 25, and 30 μl of the 
protein extract (homogenized cell solutions) were add‑
ed to multiple wells. Bradford reagent was also added 
to each well. The color density of all wells was read 
by the plate reader at 630 nm. Finally, protein quanti‑
ty in the extracts was attained by using the standard 
curve. These homogenized cell solutions, containing 
mitochondria of hippocampal cells, were subsequently 
investigated for the extent of oxidative stress and in‑
flammatory markers (Wieckowski et al., 2009; Motagh‑
inejad et al., 2017d).
Measurement of oxidative stress parameters
Evaluation of lipid peroxidation 
To evaluate lipid peroxidation, we assessed malond‑
ialdehyde (MDA), a natural by‑product. Concisely, 
100 μL of SDS lysis solution was added to wells that 
contained 100 μL of sample solution or MDA standard. 
After shaking and incubating these wells, 250 μL of 
thiobarbituric acid (TBA) reagent was added to each 
well, and wells were subsequently incubated at 95°C for 
45‑60 min. Following this incubation, the tubes were 
centrifuged at 1000 × g for 15 min and 300 μl of n‑Buta‑
nol was added to 300 μL of the supernatant. Then, the 
tubes were centrifuged for 5 min at 10,000 × g. Finally, 
absorbance was read at 532 nm and the attained results 
were expressed as nmol/mg of protein (Gheita and Ke‑
nawy, 2014; Motaghinejad et al., 2017e). 
Evaluation of GSH (glutathione) and GSSG (glutathione disulfide) 
To determine levels of GSH (glutathione) and GSSG 
(glutathione disulfide), 25 μL of the IX glutathione re‑
ductase solution and 25 μL of the IX NADPH solution 
were added to a 96‑well plate holding a standard solu‑
tion of glutathione, or a sample of homogenized solu‑
tion. Then, 50 μL of IX Chromogen was added to each 
well and mixed robustly. Finally, absorbance was read 
at 405 nm for both the GSSG/GSH standard and the 
sample. Using the standard curve, levels of GSSG/GSH 
were measured and are given as nmol/mg of protein 
(Yoo et al., 2007; Gheita and Kenawy, 2014, Motaghine‑
jad et al., 2017e). 
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Evaluation of manganese superoxide dismutase (MnSOD) activity
SOD function was evaluated using previously de‑
scribed methods (Koracevic et al., 2001; Yoo et al., 
2007). SOD activity was calculated using the following 
equation: SOD activity = {[(A blank 1 ‑ A blank 3) – (A 
sample ‑ A blank 2)] / (A blank 1 ‑ A blank 3)} x 100 
(Koracevic et al., 2001; Yoo et al., 2007). 
Evaluation of glutathione peroxidase (GPx) activity
GPx activity was evaluated using previously de‑
scribed methods (Yoo et al., 2007; Gheita and Kenawy, 
2014). GPx activity was calculated based on a change in 
absorbance [ΔA340/min], using the following equation: 
ΔA340/min=A340nm (Start) – A340nm (Stop) / Re‑
action time (min). Any change in absorbance is directly 
related to GPx function. 
GPx activity: ΔA340/min × Reaction volume (ml) × 
Dilution factor of the original sample / The extinction 
coefficient for NADPH at 340 nm × Volumes of the test‑
ed sample. 
Outcomes are given as mU/mg protein (Yoo et al., 
2007; Gheita and Kenawy, 2014). 
Evaluation of glutathione reductase (GR) activity
GR activity was evaluated using previously described 
methods (Koracevic et al., 2001, Yoo et al., 2007). GR ac‑
tivity was measured based on a variation in absorbance 
[ΔA340/min], using the following equation: 
ΔA340/min = A340nm (Start) – A340nm (Stop)/ 
Reaction time (min), wherein any alteration in absor‑
bance is directly related to GR activity. GR activity: 
ΔA340/min × Reaction volume (ml) × Dilution factor of 
the original sample / Extinction coefficient for NADPH 
at 340 nm× Volumes of the tested sample. 
Results are given as mU/mg protein (Koracevic et 
al., 2001, Yoo et al., 2007).
Evaluation of protein expression modifications 
Concentrations (i.e., expression of protein) of BDNF, 
CREB (total and phosphorylated), TNF‑α, IL‑1β, Bax, 
and Bcl‑2 in the cell lysates of hippocampal tissue 
were estimated using a commercially available ELISA 
kit (Genzyme Diagnostics, Cambridge, USA). Confer‑
ring with the guidelines of the ELISA kits, the sensi‑
tivity and specificity for the BDNF and CREB (total and 
phosphorylated) kits were less than 2 pg/ml and 74%. 
Similarly, sensitivity and specificity for the TNF‑α, 
IL‑1β, Bax, and Bcl‑2 kits were less than 5 ng/ml and 
76%. In accordance with the guides included in the kits, 
the procedure was as follows: briefly, wells containing 
sheep anti‑rat BDNF, CREB (total and phosphorylated), 
IL‑1β, and TNF‑α polyclonal antibodies (Sigma Chemi‑
cal Co., Poole, and Dorset, UK) were washed three times 
with washing buffer (0.5 M of sodium chloride [NaCl], 
2.5 mM sodium dihydrogen phosphate [NaH2PO4], 
7.5 mM Na2HPO4, 0.1% Tween 20, pH 7.2). Then, 100 µl of 
1% (w/v) ovalbumin (Sigma Chemical Co., Poole, Dorset, 
UK) solution was added to each well and incubated at 
37°C for 1 hr. Following three washes, 100 µl of samples 
and standards were added to each well and incubated 
at 48°C for 20 hrs. After three washes, 100 µl of the bi‑
otinylated sheep anti‑rat IL‑1β or TNF‑α antibodies (1: 
1000 dilutions in washing buffer containing 1% sheep 
serum, Sigma Chemical Co., Poole, and Dorset, UK) were 
added to each well. Next, after 1‑hour incubation and 
three washes, 100 ml avidin‑HRP (Dako Ltd, UK) (1: 
5000 dilution in wash buffer) was added to each well 
and the plate was incubated for 15 min. After washing 
three times, 100 µl of TMB substrate solution (Dako 
Ltd., UK) was added to each well and then incubated for 
10 min at room temperature. Then, 100 µl of 1M H2SO4 
was added and absorbance was read at 450 nm. Results 
are given in ng, as amount of IL‑1β/ml or TNF‑α/ml. 
Bax and Bcl‑2 in suspension of hippocampal tissues and 
BDNF and CREB (total and phosphorylated) are report‑
ed as pg/ml of suspension in hippocampal tissues (Ar‑
ican et al., 2005; Demircan et al., 2006; Shi et al., 2010; 
Lee et al., 2007). 
Statistical analysis
The data were analyzed using GraphPad PRISM v.6 
Software and averaged in each experimental group 
and expressed as means ± standard error of the mean 
(SEM). Then, the differences between the control and 
treatment groups were evaluated by analysis of vari‑
ance (ANOVA). To evaluate the significant of the be‑
haviors, the differences between group means were 
compared using Tukey’s post test at a significant level 
of p<0.001. 
RESULTS 
Evaluation of escape latency and traveled 
distance during training days in the MWM
MPH (10mg/kg) caused a significant increase in es‑
cape latency and traveled distance during four days 
training in the MWM as compared to the control group 
(p<0.001) (Fig. 1A and B). All doses of crocin inhibited 
the increase in escape latency and traveled distance fol‑
lowing MPH administration, evidenced by a reduction 
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in escape latency and traveled distance in the crocin 
groups as compared to MPH (10 mg/kg) treated group 
(p<0.001) (Fig. 1A and B). In addition, the group treat‑
ed with crocin alone (i.e., crocin in combination with 
normal saline) did not differ from the control group in 
escape latency and traveled distance during four days 
training of MWM (Fig. 1A and B).
Evaluation of swimming speed during training days
There was no difference in swimming speed during 
training trials across any of the animal groups (Fig. 1C).
Evaluation of percentage of time in the target 
quarter in the probe trial
10 mg/kg of MPH caused a significant decrease in 
the percentage of time that the animals spent in the 
target quarter, in comparison to the control group 
(p<0.001) (Fig. 1D). In all doses used, crocin significant‑
ly abolished MPH‑induced changes in the amount of 
time that animals were present in the target quarter 
(Fig. 1D). In the group treated with crocin alone (i.e., 
crocin in combination with normal saline) the percent‑
age of time that the animals spent in the target quarter 
in the MWM did not change significantly when com‑
pared to the control group (Fig. 1D).
Effects of various doses of crocin on MPH‑induced 
changes in locomotor activity 
As shown in Table I, animals treated with MPH 
(10 mg/kg) had a lower rate of central square entries, 
and also spent less time in the central area of the OFT 
as compared to control group (p<0.001). Our study 
indicated that crocin inhibited this effect of MPH 
in a dose‑dependent manner, and increased the fre‑
quency of central square entries and also time spent 
in the central region of the OFT in the groups treated 
DC
BA
Fig. 1. Mean escape latency (A), distance traveled (B), swimming speed (C) and percentage of time spent in the target quarter during the probe trial (D) in 
the control group and in the groups treated with 10 mg/kg of MPH and 10 mg/kg of MPH in combination with crocin (10, 20, 40, and 80 mg/kg) across all 
training days using the Morris water maze (MWM) in rats. All data are expressed as mean ± SEM (n=10). *** p<0.001 vs. control. ### p<0.001 vs. 10 mg/kg 
of MPH. MPH: Methylphenidate.
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with MPH. This difference was statistically significant 
compared to the group treated with MPH (10 mg/kg) 
alone (p<0.001) (Table I). In addition, in the group 
treated with crocin alone (i.e., crocin in combination 
with normal saline), the incidence of central square 
entries and also time spent in the central area of the 
OFT was similar as compared to in the control group 
(Table I). Animals in the control group, in comparison 
to the MPH treated group, had a higher frequency of 
rearing and ambulation distance in the OFT (p<0.001). 
Also, among the animals treated with crocin, there 
was a significant increase in ambulation distance and 
Table I. The effects of various doses of crocin on open field exploratory and locomotor activity on behavior of MPH‑treated rats. 
Group Ambulation distance (cm)
Central square  
entries




Control 115.0 ± 12.0 29.0 ± 3.0 169.0 ± 9.0 7.0 ± 1.0
MPH (10 mg/kg) 375.0 ± 18.0a 14.0 ± 2.9a 101.0 ± 6.0a 14.0 ± 3.0a
MPH (10 mg/kg) + Crocin (10 mg/kg) 252.0 ± 23.0b 17.0 ± 3.0 109.0 ± 10.0b 12.0 ± 2.0
MPH (10 mg/kg) + Crocin (20 mg/kg) 242.0 ± 12.0b 20.0 ± 3.0b 112.0 ± 12.0b 10.0 ± 2.0
MPH (10 mg/kg) + Crocin (40 mg/kg) 201.0 ± 16.0b 24.0 ± 2.0b 127.0 ± 6.0b 8.0 ± 1.0b
MPH (10 mg/kg) + Crocin (80 mg/kg)) 204.0 ± 18.0b 27.0 ± 1.0b 139.0 ± 10.0b 7.0 ± 2.0b
Crocin (80 mg/kg) 120.0 ± 14.0 28.0 ± 1.0 156.0 ± 11.0 7.0 ± 3.0
All data are presented as mean ± SEM, n=10. a p<0.001 vs. control group. b p<0.001 vs. MPH group. MPH: Methylphenidate.
DC
BA
Fig. 2. Effects of various doses of crocin (10, 20, 40, and 80 mg/kg) on MPH‑induced lipid peroxidation (A), SOD activity (B), GPx activity (C), and GR 
activity (D) in rat isolated hippocampus. All data are expressed as mean ± SEM (n=10). *** p<0.001 vs. control. ### p<0.001 vs. 10 mg/kg of MPH. MPH: 
Methylphenidate.
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rearing number in the MPH (10 mg/kg) treated group. 
This increase significantly differed from the group 
treated with MPH (10 mg/kg) alone (p<0.001) (Table I). 
Also, in the group treated with crocin alone (i.e., cro‑
cin in combination with normal saline), ambulation 
distance, rearing number, central square entries, and 
time spent in the central area of the OFT was not sig‑
nificantly different as compared to the control group 
(Table I).
Effects of various doses of crocin on MPH‑induced 
GSH/GSSG changes 
MPH (10 mg/kg) treatment markedly decreased the 
content of mitochondrial GSH, but increased the lev‑
els of GSSG as compared to the control group (p<0.001) 
(Table II). Conversely, high doses of crocin (40 and 
80 mg/kg) enhanced GSH content and decreased levels 
of GSSG levels in MPH‑treated animals, in comparison 
to the group treated with MPH alone (p<0.001) (Table II). 
Also, in the group treated with crocin alone (i.e., crocin 
in combination with normal saline), the content of mi‑
tochondrial GSH and GSSG did not significantly differ 
as compared to the control group (Table II).
Effects of various doses of crocin on MPH‑induced 
alterations in oxidative stress parameters 
MPH administration significantly increased MDA 
levels and decreased the activity level of SOD, GPx, 
and GR in comparison to the control group (p<0.001) 
(Fig. 2A, B, C, and D). Conversely, high doses of crocin 
(40 and 80 mg/kg) inhibited the MPH‑induced increase 
in MDA levels and decrease in activity of SOD, GPx, and 
GR (p<0.001) (Fig. 2 A, B, C, and D). Also, in the animals 
treated with crocin (80 mg/kg) alone (i.e., crocin in 
combination with normal saline), there was a decrease 
in MDA levels, but activity of SOD, GPx, and GR did not 
significantly differ in comparison with the control 
group (Fig. 2A, B, C and D).
Table II. The effects of various doses of crocin treatment on content of mitochondrial GSH and GSSG in MPH‑treated rats.





Control group 65.20 ± 5.10 0.88 ± 0.30 73.00
MPH (10 mg/kg) 38.20 ± 5.20a 6.20 ± 0.90a 6.10a
MPH (10 mg/kg) + Crocin (10 mg/kg) 48.60 ± 4.10 4.50 ± 0.05 10.90
MPH (10 mg/kg) + Crocin (20 mg/kg) 52.30 ± 4.00 4.45 ± 0.14 11.50
MPH (10 mg/kg) + Crocin (40 mg/kg) 56.20 ± 5.40b 3.90 ± 0.90b 14.30b
MPH (10 mg/kg) + Crocin (80 mg/kg) 60.30 ± 3.90b 3.20 ± 0.20b 18.75b
Crocin (80 mg/kg) 69.10 ± 8.20 0.82 ± 4.30 80.00
All data are presented as mean ± SEM, n=10. a p<0.001 vs. control group. b p<0.001 vs. MPH group. MPH: Methylphenidate. 
A B
Fig. 3. Effects of various doses of crocin (10, 20, 40, and 80 mg/kg) on MPH‑induced alteration in TNF‑α (A) and IL‑1β (B) levels in rat isolated hippocampus. 
All data are expressed as mean ± SEM (n=10). *** p<0.001 vs. control. ### p<0.001 vs. 10 mg/kg of MPH. MPH: Methylphenidate.
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Impact of various doses of crocin  
on MPH‑induced increase in inflammatory 
biomarkers 
10 mg/kg MPH caused a significant elevation in lev‑
els of IL‑1β and TNF‑α, as compared to the control group 
(p<0.001) (Fig. 3A and B). Conversely, high doses of cro‑
cin (40 and 80 mg/kg) prevented the MPH‑induced in‑
crease in levels of IL‑1β and TNF‑α, compared to the 
group treated with MPH alone (p<0.001) (Fig. 3A and B). 
Also, in the group treated with crocin (80 mg/kg) alone 
(i.e., crocin in combination with normal saline), IL‑1β 
and TNF‑α levels did not significantly differ from the 
control group (Fig. 3A and B).
Impact of various doses of crocin  
on MPH‑induced alterations in Bax  
and Bcl‑2 levels
MPH (10mg/kg) treatment was associated with 
increased protein expression of Bax, and reduced 
protein expression of Bcl‑2 in comparison to the con‑




Fig. 4. Effects of various doses of crocin (10, 20, 40 and 80 mg/kg) on MPH‑induced alterations in protein expression of Bcl‑2 (A), Bax (B), BDNF (C), total 
CREB (D) and phosphorylated CREB (E) in rat isolated hippocampus. All data are expressed as Mean ± SEM (n=10). *** p<0.001 vs. control. ### p<0.001 
vs. 10 mg/kg of MPH. MPH: Methylphenidate. 
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and 80 mg/kg) enhanced Bcl‑2 expression, but – in 
all examined doses, reduced Bax protein expression 
in comparison to the MPH treated group (p<0.001) 
(Fig. 4A and B). Also, in the group treated with cro‑
cin (80 mg/kg) alone (i.e., crocin in combination with 
normal saline), there was no significant difference in 
levels of Bax or Bcl‑2 level in comparison to the con‑
trol group (Fig. 4A and B).
Impact of various doses of crocin on 
MPH‑induced modification of protein expression 
in both forms of CREB and BDNF 
Relative to the control group, MPH (10mg/kg) treat‑
ment significantly decreased the protein expression of 
both total and phosphorylated forms of BDNF and CREB 
(p<0.001) (Fig. 4 C, D, and E). Conversely, in MPH‑treat‑
ed animals, administration of high doses of crocin (40 
and 80 mg/kg) considerably enhanced protein expres‑
sion of both total and phosphorylated forms of BDNF 
and CREB in comparison to the group treated with MPH 
only (p<0.001) (Fig. 4C, D, and E). Also, in the group 
treated with crocin (80 mg/kg) alone (i.e., crocin in 
combination with normal saline), BDNF and CREB (to‑
tal and phosphorylated) levels were not significant as 
compared to control group (Fig. 4C, D, and E).
DISCUSSION 
The results of the present study demonstrate that 
several doses of crocin can ameliorate MPH‑induced 
neuro‑apoptosis, oxidative stress, and inflammation in 
the rat hippocampus. In addition, the results indicate 
that the P‑CREB /BDNF signaling pathway may be an 
intermediate step in the neuroprotective role of crocin.
As a psycho‑stimulant agent, MPH has a high po‑
tential for abuse and addiction (Morton and Stockton, 
2000; Barrett et al., 2005; Martins et al., 2006; Berridge 
et al., 2006). According to the present study, chronic 
administration of MPH at a dose of 10 mg/kg was asso‑
ciated with an increase in escape latency and traveled 
distance in the MWM. These data suggest that MPH 
administration can disturb learning‑related activity. 
In addition, on probe day, we found that MPH admin‑
istration decreased the percentage of time spent that 
the rat spent in the target quarter of the MWM. These 
patterns suggest that chronic administration of MPH 
can deteriorate spatial memory – a result that confirms 
outcomes of a previous study showing that chronic 
administration of MPH was associated with a decline 
in learning and memory in rats (Scherer et al., 2010). 
MPH has been shown to cause a release of dopamine, 
serotonin, and adrenaline in the brain, causing down‑
regulation of these amine receptors, which can conse‑
quently result in cognition impairment (Berridge et al., 
2006). According to our results, high doses of crocin (40 
and 80 mg/kg) can amleiorate MPH‑induced cognition 
impairment. On the other hand, crocin alone can de‑
crease escape latency and traveled distance, and also 
increase the presence of the animal in the target quar‑
ter in the MWM. Several previous studies have indi‑
cated that crocin and other similar herbal compounds 
can improve learning and memory (Hosseinzadeh et 
al., 2012). The results of the present study demonstrate 
that MPH at a dose of 10 mg/kg leads to a decrease 
in central square entry and time spent in the central 
square in the OFT, and can also increase ambulation 
distance and rearing number. According to these data, 
this dose of MPH can cause hyper‑locomotion and re‑
sult in the manifestation of depressive‑like behavior. 
This dose of MPH likely causes a disturbance, specif‑
ically an increase, in motor activity (Kanazawa et al., 
2017). On the other hand, our results show that crocin 
can decrease this type of depression in a dose‑depen‑
dent manner, and can cause inhibition of MPH‑induced 
hyper‑locomotion and motor activity disturbance in 
the OFT. In addition, crocin alone can increase central 
square entry and the time spent in the central square 
in the OFT, and reduce ambulation distance and rear‑
ing number (Itzhak and Martin, 2002; Barbosa et al., 
2011). Our results are consistent with a previous study 
demonstrating that a crocin‑like derivative (i.e., quer‑
cetin) can alter manic‑like behavior and hyper‑locomo‑
tion induced by MPH (Kanazawa et al., 2017). Several 
previous studies have demonstrated that crocin can act 
as an antidepressant and modulate motor activity dis‑
turbances (Hosseinzadeh et al., 2004, Wang et al., 2010). 
It has been previously proposed that crocin can mod‑
ulate cortical excitability, motor activity, and reaction 
speed in depressed individuals (Jam et al., 2017). A re‑
lated study demonstrated that chronic administration 
of quercetin blocked MPH‑stimulated hyper‑locomo‑
tion in mice, which may reflect an antimanic‑like effect 
(Kanazawa et al., 2017). 
Our data indicate that MPH administration induc‑
es a rise in hippocampal MDA levels; however, cro‑
cin treatment (10, 20, 40, and 80 mg/kg) attenuated 
the MPH‑induced increase in lipid peroxidation in 
the brain. The inhibitory influence of crocin on MDA 
levels was more pronounced at higher doses (40 and 
80 mg/kg) in comparison to the lower doses (10 and 
20 mg/kg) used in this study. Crocin alone (80 mg/kg) 
was also found to decrease MDA levels. These outcomes 
are similar to prior findings, which showed MPH‑in‑
duced lipid peroxidation in the brain ( Martins et al., 
2006; Schmitz et al., 2012). According to these data, it 
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appears that part of the damaging effects of MPH are 
mediated by mitochondrial dysfunction, and crocin 
may play a role in moderating this process (Fagundes et 
al., 2010). Moreover, it has been indicated by prior work 
that crocin exerts neuroprotective properties by inhib‑
iting the creation of free radicals in neurodegenerative 
diseases such as Alzheimer’s disease (Hosseinzadeh et 
al., 2009; Khalili and Hamzeh, 2010; Rashedinia et al., 
2015). In addition, the role of crocin as a scavenger of 
free radicals is apparent in this type of disorder (Hos‑
seinzadeh et al., 2005; Naghizadeh et al., 2008). Our re‑
sults showed that MPH (10 mg/kg) reduces the content 
of mitochondrial GSH, but increases levels of GSSG in 
hippocampal tissues. The conversion of GSH to GSSG by 
MPH is a main step that can start and trigger neurode‑
generative signals in the brain (Martins et al., 2006; Fa‑
gundes et al., 2010), and this mechanism has damaging 
effects on the glutathione cycle and thus causes neural 
cell death ( Martins et al., 2006; Fagundes et al., 2010). 
Furthermore, we found that several doses of crocin, 
particularly 40 and 80 mg/kg, increase GSH content 
while decreasing GSSG levels in animals treated with 
MPH (10 mg/kg). Crocin alone (80 mg/kg) was found to 
decrease GSSG levels and increase GSH levels. These re‑
sults have been previously described by studies report‑
ing that, by modulating the glutathione cycle, crocin 
can be therapeutically advantageous against neurode‑
generative diseases as it stimulates GSH development 
(Ochiai et al., 2004a; 2004b).
In the present study, MPH administration reduced 
the activity of GPx, GR, and SOD in isolated hippocam‑
pal tissues. These results confirm prior reports that 
MPH abuse can reduce antioxidant defenses which 
may, in turn, result in neurodegeneration (Martins et 
al., 2006). It has been shown that GR is the key enzyme 
modulating the glutathione cycle (Hosseinzadeh et al., 
2005). Thus, the MPH‑induced reduction in GR activity 
results in an elevation in GSSG levels and a reduction 
in GSH levels, as observed in our results. Several re‑
cent reports demonstrate that MPH consumption leads 
to mitochondrial dysfunction and inhibits antioxidant 
enzyme activity in multiple cells, and these properties 
can cause MPH‑induced degenerative effects on brain 
cells, such as in the hippocampus (Martins et al., 2006; 
Lagace et al., 2006). We found that crocin recovers the 
action of antioxidant enzymes in a dose‑dependent 
manner. Crocin alone (80 mg/kg) was able to activate 
antioxidant enzymes. By stimulating GR, crocin en‑
hances the conversion of GSSG to GSH and therefore, 
protects the brain against MPH‑induced oxidative 
stress. Other experimental studies have also estab‑
lished that the observed anti‑oxidative properties of 
crocin in neurodegenerative disorders and diseases are 
mediated by an increase in activity of GR and GPx (Bors 
et al., 1984; Ochiai et al., 2004a). Moreover, a similar 
previous study demonstrated that prolonged quercetin 
treatment blocked the MPH‑induced increase in oxi‑
dative stress (Kanazawa et al., 2017). Also, our results 
confirm prior studies showing a decrease in SOD action 
following MPH abuse (Lagace et al., 2006; Martins et al., 
2006). Consistent with prior studies, crocin treatment 
was found to be effective in reversing the alcohol‑in‑
duced decrease in SOD action in the hippocampal tis‑
sues (Ochiai et al., 2004a). 
We confirmed that prolonged MPH administration 
significantly raises levels of pro‑inflammatory cyto‑
kines such as IL‑1β and TNF‑α in hippocampal tissue. 
We also found that, in high doses, crocin has robust po‑
tential for suppressing MPH‑induced neuroinflamma‑
tion, and this effect is dose‑dependent. Further, treat‑
ment of the animals by crocin alone (80 mg/kg) was 
found to inhibit the inflammatory biomarkers IL‑1β 
and TNF‑α. Our results are consistent with prior stud‑
ies showing an increase in pro‑inflammatory cytokines 
following abuse of MPH and other psychostimulants. It 
has been proposed that the MPH‑induced increase in 
inflammation is a likely cause of the neurotoxic prop‑
erties of MPH (Martins et al., 2006). Alternatively, cro‑
cin has been shown to have therapeutic potential for 
the management of neuroinflammation signaling cas‑
cades, thus protecting the brain against inflammation 
and related damage (Mehri et al., 2012).
Moreover, with respect to oxidative stress and in‑
flammation, the present study confirms MPH‑induced 
apoptosis in the hippocampus. According to the cur‑
rent study, administration of MPH increased the levels 
of the apoptotic protein, Bax, while simultaneously re‑
ducing levels of the anti‑apoptotic protein, Bcl‑2. These 
data are consistent with previous studies demonstrat‑
ing that MPH abuse can cause brain impairment via 
triggering multiple apoptotic cascades (Andreazza et 
al., 2007; Bethancourt et al., 2009). At the same time, 
our results verified the anti‑apoptotic effects of crocin 
against MPH administration, as shown by a reduction 
in Bax expression and an increase in Bcl‑2 expression 
in the hippocampus. Indeed, we found that crocin 
alone (80 mg/kg) was able to decrease Bax levels and 
increase Bcl‑2 levels. Previous studies confirmed that 
crocin treatment reduces cleaved caspase‑3, the pro‑
duction of Bax, and nuclear condensation resulting 
from some neurodegenerative disorder and diseases 
(Oruc et al., 2016). 
The anti‑inflammatory, anti‑apoptotic and anti‑ox‑
idative properties of crocin have been formerly de‑
scribed (Mehri et al., 2012; Rameshrad et al., 2018), and 
are consistent with our work; however, the involved 
signaling pathways remain unknown. To address this, 
we assessed the role of the P‑CREB‑BDNF signaling 
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pathway and aimed to identify the involved signal‑
ing pathway. Our data confirmed that administration 
of MPH ameliorates protein expression of CREB (total 
and phosphorylated) and BDNF in the hippocampus. 
In contrast, in high does, crocin treatment enhances 
protein expression of CREB (total and phosphorylated) 
and BDNF. Therefore, these results indicate that crocin 
treatment restores the P‑CREB‑BDNF signaling cascade 
and protects the brain against MPH‑induced neurotox‑
icity. As a transcription factor, P‑CREB controls over 
a hundred target genes, particularly BDNF, which is 
involved in neuronal regeneration, development, sur‑
vival, excitability, addiction, depression, and cognition 
(Carlezon et al., 2005). Furthermore, dysregulation of 
the CREB transcriptional cascade has been found to 
prompt oxidative stress, apoptosis, and neurodegener‑
ation (Mayr and Montminy, 2001; Carlezon et al., 2005). 
Previous molecular studies have consistently reported 
that the phosphorylated form of CREB plays a key role 
in various herbal and chemical neuroprotective pro‑
cesses (Mayr and Montminy, 2001). Based on the re‑
sults of numerous studies, P‑CREB (the activated form 
of CREB) leads to the creation of BDNF, which is a li‑
gand of the TrkB receptor. These studies demonstrate 
that, by stimulating its own receptor (TrkB), BDNF can 
protect brain cells from degeneration and can promote 
the survival of neurons (Martinowich et al., 2003). In 
the present study, it appears that a reduction of P‑CREB 
protein levels, via MPH, can affect the aforementioned 
BDNF/TrkB signaling cascade, which triggers neuro‑
degeneration, apoptosis, inflammation, and oxidative 
stress. Administration of crocin, in contrast, can inhib‑
it the reported toxic actions of MPH and trigger the 
cascade of P‑CREB/BDNF/TrkB. Indeed, administra‑
tion of crocin alone (80 mg/kg) activates expression 
of both P‑CREB and BDNF. As our data demonstrate, 
crocin alone can modulate cognition and motor activ‑
ity and also inhibit the occurrence of oxidative stress, 
inflammation, and apoptosis. Thus, thus it seems that 
crocin has neuroprotective properties and its adminis‑
tration alone not only has no adverse effects, but has 
protective and beneficial molecular and behavioral ef‑
fects. The initial aim of this experimental group (i.e., 
treatment of crocin alone in high dose) was to test 
the safety of crocin after a longer period of time. As 
noted, for all parameters, we found that crocin treat‑
ment alone had beneficial molecular and biochemical 
effects. Consistent with our results, it has been shown 
that the P‑CREB‑BDNF signaling pathway is associat‑
ed with a modification of numerous functions in the 
brain, such as learning, memory, mood balances, and 
reward mechanisms (Martinowich et al., 2003; Yoshii 
and Constantine‐Paton, 2010; Cao et al., 2013; Razavi 
et al., 2017). 
CONCLUSION 
The results of the present study demonstrate that 
treatment with crocin – one of the main compounds of 
saffron – can reduce MPH‑induced cognitive impair‑
ment, hyper‑locomotion, and can inhibit apoptosis, 
oxidative stress, and inflammation in rats. Based on 
these data, crocin may act as a neuroprotective medi‑
ator against the reported adverse neurobehavioral and 
neurochemical effects of MPH. According to our study, 
crocin has neuroprotective properties in this manner, 
potentially via stimulation of the P‑CREB‑BDNF sig‑
naling pathway, and this concept was summarized in 
Fig. 5. Via the aforementioned neuroprotective prop‑
erties, crocin could be a candidate treatment approach 
for inhibiting the adverse effects of drug abuse in hu‑
mans. Indeed, crocin may act as neuroprotective and 
adjunct agent against the adverse neurobehavioral and 
neurochemical effects of drug abuse in humans. 
LIMITATION OF THE STUDY
One limitation of the current study was that we did 
not evaluate the side effects of crocin at high doses, 
because the primary goal of this study was to introduce 
its neuroprotective effects against MPH‑induced se‑
quelae. An evaluation of potential side effects of crocin 
treatment was not the aim of our research. However, as 
mentioned previously, our studies have demonstrated 
that crocin in high doses (80 mg/kg) can not only affect 
the side effects on behavioral and molecular aspects, 
but also had protective effects in the rat hippocampus. 
Fig. 5. Possible role of CREB‑BDNF signaling pathway in crocin antioxidant, 
anti‑inflammatory and anti‑apoptotic effects against methylphenidate‑in‑
duced neurochemical sequels. 
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Also, the condition and effects of MPH dependency in 
human and animals are different and cannot be ex‑
trapolated to human beings. We suggest that further 
studies should evaluate the translational relevance in 
humans, as well as, dosage and toxicity of both MPH 
and crocin, to better evaluate the effects and possible 
side effects.
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